With 8.83 million shares changed hands, the volume of the stock remained heavier than its average volume of 6.93 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.1850 whereas the lowest price it dropped to was $2.0550. The 52-week range on GERN shows that it touched its highest point at $3.73 and its lowest point at $1.68 during that stretch. It currently has a 1-year price target of $4.75. Beta for the stock currently stands at 0.54.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GERN was up-trending over the past week, with a rise of 1.21%, but this was up by 14.21% over a month. Three-month performance surged to 5.03% while six-month performance fell -15.73%. The stock lost -27.43% in the past year, while it has lost -0.95% so far this year. A look at the trailing 12-month EPS for GERN yields -0.32 with Next year EPS estimates of -0.12. For the next quarter, that number is -0.10. This implies an EPS growth rate of 0.00% for this year and 63.02% for next year. EPS is expected to grow by 5.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -16.08%.
Float and Shares Shorts:
At present, 544.91 million GERN shares are outstanding with a float of 447.58 million shares on hand for trading. On Feb 15, 2024, short shares totaled 43.57 million, which was 8.02% higher than short shares on Jan 12, 2024. In addition to Dr. John A. Scarlett M.D. as the firm’s Chairman of the Board, President & CEO, Ms. Aron Feingold serves as its Vice President of Investor Relations & Corporate Communications.
Institutional Ownership:
Through their ownership of 73.00% of GERN’s outstanding shares, institutional investors have majority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GERN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, GERN has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and GERN currently yields $0.00. In the past year, GERN’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, GERN has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.
Summary of Insider Activity:
Insiders traded GERN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 116,021 while 70,000 shares were sold.
